Outpatient supportive care for pediatric acute myeloid leukemia: a single institution's experience.
Renee PotashnerMark E WeinblattChana L GlasserPublished in: Pediatric hematology and oncology (2021)
Infections are responsible for most treatment-related morbidity and mortality in pediatric acute myeloid leukemia (AML). Children's Oncology Group (COG) recommends hospitalization following chemotherapy until early absolute neutrophil count (ANC) recovery. No standard guidelines exist for antibiotic prophylaxis and discharge practices vary. Our objective was to report our institution's experience with outpatient supportive care management following early discharge. A retrospective chart review of pediatric AML patients treated at our institution from 2010 to 2019 was conducted. Data was collected on length of hospitalization, antibiotics administered, infections, and neutropenia duration. Seventeen patients underwent 60 chemotherapy cycles. All were discharged after completion of chemotherapy if clinically stable. Patients were re-admitted for fever and discharged on empiric antibiotics if afebrile with negative cultures. Prophylactic antibiotics were administered in 55 cycles. There were 12 infections in 11 patients and no deaths due to infection. Patients remained outpatient for a mean of 15.8 neutropenia days per cycle. Outpatient supportive care for children with AML may be feasible and safe. Further studies are needed to establish outpatient supportive care guidelines.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- palliative care
- chronic kidney disease
- prognostic factors
- primary care
- peritoneal dialysis
- quality improvement
- patient reported outcomes
- radiation therapy
- squamous cell carcinoma
- clinical practice
- deep learning
- locally advanced
- drug induced
- allogeneic hematopoietic stem cell transplantation
- smoking cessation
- peripheral blood
- combination therapy